Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2000
10/19/2000WO2000061136A1 Anticonvulsant derivatives useful in lowering blood pressure
10/19/2000WO2000061135A1 Method for the treatment of incontinence
10/19/2000WO2000061134A1 Antimicrobial agents
10/19/2000WO2000061133A1 Combination preparation for treating malaria
10/19/2000WO2000061132A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000WO2000061131A1 Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus angelicae containing same
10/19/2000WO2000061130A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood
10/19/2000WO2000061129A2 S-hydroxynefazodone
10/19/2000WO2000061128A2 R-hydroxynefazodone
10/19/2000WO2000061127A2 Use of insulin sensitisers for improving ketosis
10/19/2000WO2000061126A2 Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators
10/19/2000WO2000061125A2 Osanetant in the treatment of mood disorders
10/19/2000WO2000061124A2 Use off cell membrane penetrating indigoid bisindole derivatives
10/19/2000WO2000061123A2 Compound preparation made of vitamin d metabolites or vitamin d analogues and an oestrogenic component for treating osteoporosis
10/19/2000WO2000061122A2 Use of 6-methylmercaptopurine riboside in ophthalmologic compositions
10/19/2000WO2000061116A2 Pharmaceutical formulation comprising amoxycillin and clavulanate
10/19/2000WO2000061115A2 Pharmaceutical formulation comprising amoxycillin
10/19/2000WO2000061112A2 Solubilized pharmaceutical composition for parenteral administration
10/19/2000WO2000061111A1 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
10/19/2000WO2000061106A1 Antimicrobial wipes which provide improved immediate germ reduction
10/19/2000WO2000061097A1 External preparation compositions
10/19/2000WO2000061095A1 Use of a synergistic mixture of polyphenols and vitamin compounds in cosmetic and dermatological compositions and methods for capturing free radicals on the skin and skin appendices
10/19/2000WO2000061069A2 Methods and compositions for use in the treatment of hyperlipidemia
10/19/2000WO2000061068A2 Anthelmintic compositions
10/19/2000WO2000060956A1 Hydrogel-forming system with hydrophobic and hydrophilic components
10/19/2000WO2000060952A1 Method of using emamectin to treat fish parasites
10/19/2000WO2000060939A1 Lubrication composition
10/19/2000WO2000060932A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000WO2000042992A3 Compositions and methods for mucosal delivery
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000038620A3 A composition useful to treat periodontal disease
10/19/2000WO2000037063A3 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
10/19/2000WO2000035420A3 Stable surgical irrigating solutions
10/19/2000WO2000034780A3 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
10/19/2000WO2000034308A3 Protein transduction system and methods of use thereof
10/19/2000WO2000034296A3 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
10/19/2000WO2000033823A3 Methods of using temozolomide in the treatment of cancers
10/19/2000WO2000033787A3 Deodorant cosmetic composition
10/19/2000WO2000032769A3 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides
10/19/2000WO2000024405A9 Compounds and their therapeutic use with diabetic complications
10/19/2000WO2000023022A8 Method and compositions for in situ formation of protective and/or medicated films on body tissue
10/19/2000WO2000019883A9 Compositions and methods of disease diagnosis and therapy
10/19/2000WO2000012720A8 Elongase genes and uses thereof
10/19/2000WO2000012507A8 Pyrrolobenzodiazepines
10/19/2000WO2000009070A3 Inhibition of pathogenic processes related to tissue trauma
10/19/2000WO2000007996A8 Pyrazoles as estrogen receptor modulators
10/19/2000DE19917930A1 Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity
10/19/2000DE19917505A1 Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
10/19/2000DE19917233A1 New stable, soluble crystalline sodium salt of 5-chloro-2-methoxy-N-(2-phenylethyl)-benzamide derivative, is an ATP-sensitive potassium channel blocker useful e.g. for treating cardiac arrhythmia or ischemia
10/19/2000DE19916837A1 New di- or tetrahydro-benzoazulene derivatives, are integrin inhibitors useful e.g. for treating thrombosis, coronary heart disease, arteriosclerosis, tumors, osteoporosis or rheumatoid arthritis
10/19/2000DE19916719A1 Neue ECE-Inhibitoren, ihre Herstellung und Verwendung New ECE inhibitors, their preparation and use
10/19/2000DE19916419A1 Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einer östrogenen Komponente zur Behandlung von Osteoporose A combination preparation of vitamin D metabolites or vitamin D analogues and of an estrogenic component in the treatment of osteoporosis
10/19/2000DE19915602A1 3-Amino-4-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung 3-amino-4-arylpropan-1-ol-derivatives, their preparation and use
10/19/2000DE19915601A1 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung 3-amino-3-arylpropan-1-ol-derivatives, their preparation and use
10/19/2000DE19915485A1 Therapie der Herzinsuffizienz Treatment of heart failure
10/19/2000CA2760534A1 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
10/19/2000CA2696826A1 Process for preparing inhibitors of nucleoside metabolism
10/19/2000CA2403209A1 Synthesis of biologically active compounds in cells
10/19/2000CA2382628A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000CA2371223A1 49 human secreted proteins
10/19/2000CA2371172A1 50 human secreted proteins
10/19/2000CA2370523A1 49 human secreted proteins
10/19/2000CA2370425A1 Pharmaceutical compounds
10/19/2000CA2370406A1 Pharmaceutical compounds
10/19/2000CA2370237A1 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2000CA2370131A1 62 human secreted proteins
10/19/2000CA2370007A1 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
10/19/2000CA2370000A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
10/19/2000CA2369981A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
10/19/2000CA2369971A1 Aryl or heteroaryl fused imidazole derivatives, their pharmaceutical compositions and agents, and uses thereof
10/19/2000CA2369732A1 R-hydroxynefazodone
10/19/2000CA2369728A1 Substituted bicyclic heteroaryl compounds as integrin antagonists
10/19/2000CA2369684A1 Novel method of treatment
10/19/2000CA2369670A1 Indigoid bisindole derivatives
10/19/2000CA2369666A1 N-substituted-n'-substituted urea derivatives and the use thereof as tnf-.alpha production inhibitory agents
10/19/2000CA2369662A1 Prostaglandin e1 derivatives
10/19/2000CA2369654A1 N-substituted-n'-substituted urea derivatives and pharmaceutical compositions containing said derivatives
10/19/2000CA2369638A1 Use of osanetant in the production of medicaments used to treat mood disorders
10/19/2000CA2369629A1 Method to type prion proteins
10/19/2000CA2369578A1 Compounds and methods for therapy and diagnosis of lung cancer
10/19/2000CA2369454A1 Uses of mammalian ox2 protein and related reagents
10/19/2000CA2369420A1 Treatment of myeloma bone disease with proteasomal and nf-kb activity inhibitors
10/19/2000CA2369413A1 Transmembrane protein expressed in prostate and other cancers
10/19/2000CA2369381A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
10/19/2000CA2369303A1 Method and composition for the treatment of cancer
10/19/2000CA2369301A1 Management of pain after joint surgery
10/19/2000CA2369299A1 Inhibitor of visual function disturbance caused by optic nerve cell disorder due to factor other than ophthalmic circulatory disorder
10/19/2000CA2369272A1 Medicinal compositions and their method of preparation
10/19/2000CA2369263A1 Methods and compositions for enhancing delivery of therapeutic agents to tissues
10/19/2000CA2369230A1 Anticonvulsant derivatives useful in maintaining weight loss
10/19/2000CA2369225A1 S-hydroxynefazodone
10/19/2000CA2369156A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000CA2369089A1 Combination preparation for treating malaria
10/19/2000CA2369084A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood
10/19/2000CA2369029A1 Poly(dipeptide) as a drug carrier
10/19/2000CA2368840A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors
10/19/2000CA2368829A1 Adamantane derivatives
10/19/2000CA2368648A1 Estrogen receptors and bone
10/19/2000CA2368369A1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/19/2000CA2368049A1 Integrin receptor ligands
1 ... 6225 6226 6227 6228 6229 6230 6231 6232 6233 6234 6235 6236 6237 6238 6239 6240 6241 6242 6243 6244 6245 ... 7860